Superiority of 6-[<sup>18</sup>F]-Fluorodopamine Positron Emission Tomography<i>Versus</i>[<sup>131</sup>I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic PheochromocytomaΙoannis Ilias, Karel Pacák, Juan Yu et al.|The Journal of Clinical Endocrinology & Metabolism|2003Cited by 240
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerJorge A. Carrasquillo, Michael J. Morris, Howard I. Scher et al.|European Journal of Nuclear Medicine and Molecular Imaging|2013Cited by 182
Comparison of 6-<sup>18</sup>F-Fluorodopamine PET with <sup>123</sup>I-Metaiodobenzylguanidine and <sup>111</sup>In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic PheochromocytomaΙoannis Ilias, Karel Pacák, Clara C. Chen et al.|Journal of Nuclear Medicine|2008Cited by 149
The Role of [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography and [<sup>111</sup>In]-Diethylenetriaminepentaacetate-<scp>d</scp>-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing’s SyndromeKarel Pacák, Lynnette K. Nieman, Ιoannis Ilias et al.|The Journal of Clinical Endocrinology & Metabolism|2004Cited by 138
Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sitesMarcelo Mamede, Karel Pacák, Jorge A. Carrasquillo et al.|Nuclear Medicine Communications|2005Cited by 91